29
Jul

Looking to share some of the spotlight focused on the immuno-oncology arena, Merck Serono says it has launched a mid-stage study of MSB0010718C, an anti-PD-L1 antibody.

…read more

Source: Merck Serono steps into IO spotlight with PhII cancer study

    

0 No comments